Haleon, a global leader in consumer health, announced Monday the appointment of Richard Manso as U.S. chief marketing officer, effective April 27.
The move signals a strategic shift for the Warren-based company—home to household brands like Sensodyne, Advil and Centrum—as it seeks to integrate advanced data and AI-driven technology into its consumer engagement strategy.
In his new role, Manso will report directly to Nathalie Gerschtein, CEO of U.S. & President of North America. His mandate is to accelerate Haleon’s transformation into a more agile, consumer-centric organization that meets the rising demand for personalized, on-demand health experiences.
Manso will oversee the integrated U.S. marketing organization, focusing on high-priority growth areas including:
- Medicare Advantage OTC: Navigating the complex supplemental benefits landscape.
- GLP-1 Support: Addressing the evolving needs of consumers using weight-loss medications.
- Specialized Platforms: Advancing marketing efforts in Women’s and Pediatric Health.
“Consumers are taking a more active role in managing their health—and that’s raising expectations for the brands they trust,” Gerschtein said. “Richard brings a forward-looking perspective at the intersection of marketing, data, and technology that will help us continue to evolve and deliver better everyday health with humanity.”
Manso joins Haleon following a tenure in senior leadership at Google, where he spearheaded large-scale B2B marketing programs and drove the adoption of data and AI-enabled solutions. His background in digital strategy and tech-driven marketing is expected to bridge the gap between traditional consumer health care and the modern, data-led marketing ecosystem.
“As people take greater ownership of their health, there’s a real opportunity to rethink how brands show up, not just as products, but as trusted partners in everyday life,” Manso said. “I’m looking forward to bringing together data, technology, and creativity to build more meaningful connections.”
